E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« IPO Submits Commentary on USPTO Bilski Interim Guidance | Main | Biotech/Pharma Docket »

October 07, 2010

Comments

Though there has been some (perhaps fair) griping that Bayh-Dole has at times inappropriately influenced the research process in favor of commercialization, nonetheless it's hard to argue with the numbers. Patent law demonstrably benefits the economy, and its improved partnership with academia has enhanced this state of affairs.
http://www.wired.com/epicenter/2010/10/google-oracle-android/comment-page-1/#ixzz11WHFGiuV

The comments to this entry are closed.

March 2017

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31